您好！本问卷旨在了解公众及相关群体对干细胞生物科技企业在商业模式创新、产品与服务升级、信息管理、风险控制及市场发展等方面的看法。问卷仅用于学术研究，所有信息将匿名处理。感谢您的支持与参与！
Hello! This questionnaire aims to understand public and stakeholder views on business model innovation, product and service upgrading, information management, risk control, and market development of stem cell biotechnology enterprises. All responses will be used for academic research only and will remain anonymous. Thank you for your participation.
1. 您的身份更接近以下哪一类？Which of the following best describes your identity? A. 普通消费者 / General consumer B. 潜在患者或有健康管理需求者 / Potential patient or person with health management needs C. 创业者或投资关注者 / Entrepreneur or investor D. 医疗健康行业从业者 / Healthcare industry practitioner E. 社区或公共服务相关人员 / Community or public service related personnel F. 其他 / Other
2. 您是否了解干细胞技术或相关生物科技服务？How familiar are you with stem cell technology or related biotechnology services? A. 非常了解 / Very familiar B. 比较了解 / Fairly familiar C. 一般了解 / Generally familiar D. 了解较少 / Slightly familiar E. 完全不了解 / Not familiar at all
3. 您认为当前干细胞生物科技企业最需要提升的是哪一方面？In your opinion, which area do stem cell biotechnology enterprises most need to improve? A. 产品技术水平 / Product technology level B. 服务流程与客户体验 / Service process and customer experience C. 市场推广与品牌宣传 / Marketing and brand promotion D. 合规管理与安全保障 / Compliance management and safety assurance E. 价格透明度与收费合理性 / Price transparency and reasonable charges F. 数字化平台建设 / Digital platform development
4. 您认为影响您选择干细胞相关服务的最重要因素是什么？What is the most important factor influencing your choice of stem cell-related services? A. 技术安全性 / Technical safety B. 企业合法合规性 / Legality and compliance of the enterprise C. 服务质量 / Service quality D. 价格水平 / Price level E. 企业口碑与品牌信任 / Enterprise reputation and brand trust F. 个性化服务方案 / Personalized service plans
5. 您认为企业进行“产品—服务升级”后，最可能带来的积极影响是什么？In your opinion, what is the most likely positive effect of “product-service upgrading” for the enterprise? A. 提高客户信任度 / Increasing customer trust B. 提升市场竞争力 / Enhancing market competitiveness C. 增强客户满意度 / Improving customer satisfaction D. 促进企业盈利能力提升 / Promoting enterprise profitability E. 扩大市场覆盖范围 / Expanding market coverage F. 提高企业规范化水平 / Improving enterprise standardization
6. 您是否认可企业通过数字化方式提升服务质量，例如客户平台、数据追踪、在线咨询等？Do you agree with the use of digital methods to improve service quality, such as customer platforms, data tracking, and online consultation? A. 非常认可 / Strongly agree B. 比较认可 / Agree C. 一般 / Neutral D. 不太认可 / Disagree E. 完全不认可 / Strongly disagree
7. 您认为干细胞生物科技企业当前面临的最大风险是什么？In your opinion, what is the biggest risk currently faced by stem cell biotechnology enterprises? A. 政策法规变化风险 / Risk of changes in policies and regulations B. 数据安全与隐私泄露风险 / Data security and privacy leakage risk C. 技术研发失败风险 / Risk of technology R&D failure D. 市场接受度不足 / Insufficient market acceptance E. 运营成本过高 / High operating costs F. 行业竞争加剧 / Intensified industry competition
8. 您认为企业在信息管理方面最应该重视哪项内容？In terms of information management, what should enterprises pay the most attention to? A. 客户个人信息保护 / Protection of customers’ personal information B. 业务数据的准确性 / Accuracy of business data C. 实时监控与风险预警 / Real-time monitoring and risk warning D. 各管理层之间的信息共享 / Information sharing among different management levels E. 决策支持系统建设 / Development of decision-support systems F. 员工信息化操作培训 / Staff training in information technology operations
9. 您认为以下哪种发展策略最有助于企业保持长期竞争力？Which of the following strategies do you think is most helpful for enterprises to maintain long-term competitiveness? A. 加强与医院或科研机构合作 / Strengthening cooperation with hospitals and research institutions B. 推动数字化转型 / Promoting digital transformation C. 提供个性化健康管理服务 / Providing personalized health management services D. 扩大市场宣传与渠道建设 / Expanding marketing and distribution channels E. 强化产品研发与质量控制 / Strengthening product R&D and quality control F. 加强政策合规与风险管理 / Enhancing policy compliance and risk management
10. 您对干细胞生物科技企业未来在产品、服务、管理或风险控制方面还有哪些建议？What suggestions do you have for the future development of stem cell biotechnology enterprises in terms of products, services, management, or risk control?